Evidence map›Paper›PMID 38842141›Full record

ArticlePsychiatry and clinical neurosciences2024

The association between levels of brain-derived neurotrophic factor and comorbid depression in patients with cardiovascular disease: The Framingham Heart Study.

Sara Medved, Joel Salinas, Daniel Kojis, Galit Weinstein, Ramachandran S Vasan, Alexa Beiser, Sudha Seshadri

Abstract read
In one paragraph

Article in Psychiatry and clinical neurosciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sara MedvedDepartment of Psychiatry and Psychological Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.ORCID https://orcid.org/0000-0001-8079-3079
Joel SalinasDepartment of Neurology, New York University Grossman School of Medicine, New York, New York, USA.
Daniel KojisDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
Galit WeinsteinSchool of Public Health, University of Haifa, Haifa, Israel.
Ramachandran S VasanBoston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA.
Alexa BeiserDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
Sudha SeshadriBoston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA.

Funding

FRAMINGHAM HEART STUDY - YEAR 5 EXAM75N92019D00031 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · 2019 to 2024
$29.8M
South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Neela K Patel · 2021 to 2026
$24.0M
PRECURSORS OF STROKE INCIDENCE AND PROGNOSISR01NS017950 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Hugo Javier Aparicio, Jose Rafael Romero · 1985 to 2026
$22.9M
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham CohortsR01AG054076 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DECARLI, CHARLES, SESHADRI, SUDHA · 2016 to 2020
$12.3M
Multidimensional Assessment of Brain Health as A Marker of Dementia Risk and ResilienceR01AG066524 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KASHANI, AMIR H, RAMACHANDRAN, VASAN S · 2020 to 2024
$9.7M
Cognitively Healthy Nonagenarians in the Cross Cohort Collaboration (CCC)RF1AG059421 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SESHADRI, SUDHA · 2018 to 2018
$6.1M
Cognitively Healthy Nonagenarians in the Cross Cohort Collaboration (CCC)R01AG059421 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Stephanie Anne-Carine Debette, Carole Dufouil · 2026 to 2026
$4.7M
THE UNIVERSITY OF TEXAS HOUSTON STROKE TRAINING PROGRAMT32NS007412 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SAVITZ, SEAN I · 1998 to 2023
$4.6M
Plasma Proteome and Risk of Alzheimer Dementia and Related Endophenotypes in the Framingham StudyRF1AG063507 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GERSZTEN, ROBERT E, RAMACHANDRAN, VASAN S · 2019 to 2019
$4.2M
Imaging Genomics of the Aging BrainR01AG058464 · NIA · YALE UNIVERSITY · PI BLANGERO, JOHN, GLAHN, DAVID C · 2018 to 2022
$3.9M
SARS-CoV-2 and Precursors of Alzheimer's Disease and Related Dementias: An Ultrahigh Field (7T) MRI Study in a Diverse Multinational CohortR56AG074467 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GIRARD, TIMOTHY D, HOSSEINI, AKRAM A. · 2021 to 2021
$3.5M
Identification of a missing key element underlying apoE2 neuroprotection in Alzheimer's disease and the aging brainRF1AG061872 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HAN, XIANLIN, SESHADRI, SUDHA · 2018 to 2018
$3.4M
NHLBI NIH HHS 75N92019D00031NHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INHLBI NIH HHS N01 HC025195NIA NIH HHS AG058464NIA NIH HHS AG059421NIA NIH HHS AG061872NIA NIH HHS AG063507NIA NIH HHS AG079282NIA NIH HHS P30 AG066546NIA NIH HHS P30AG066546NIA NIH HHS R01 AG054076NIA NIH HHS R01 AG058464NIA NIH HHS R01 AG066524NIA NIH HHS R01 AG079282NIA NIH HHS R56 AG074467NIA NIH HHS RF1 AG059421NIA NIH HHS RF1 AG061872NIA NIH HHS RF1 AG063507NINDS NIH HHS R01 NS017950NINDS NIH HHS T32 NS007412NINDS NIH HHS UF1 NS125513
6 · The paper itself

Abstract

aimThe current study aims to investigate the association of serum brain-derived neurotrophic factor (BDNF) levels with symptoms of depression in adults with and without prevalent cardiovascular disease (CVD), an often burdensome comorbidity.

methodsThis cross-sectional study included participants from FHS (Framingham Heart Study) who had available serum BDNF levels. Depressive symptoms were assessed using the Center for Epidemiological Studies-Depression Scale (CES-D) with a score ≥16 indicating mild to moderate and ≥21 severe depression. Participants taking antidepressant medications were excluded from the study.

resultsAltogether 3716 FHS participants were included in the final analysis (mean age, 64.3 ± 11.5 years; 55% women). After adjusting for potential confounders, greater BDNF levels were associated with reduced severe depression risk (odds ratio [OR], 0.78 [95% CI, 0.64-0.96]; P = 0.016). Among participants with CVD, greater BDNF levels were related to lower risk of depressive symptoms (CES-D ≥ 16 OR, 0.63 [95% CI, 0.45-0.89], P = 0.008; CES-D ≥ 21 OR, 0.49 [95% CI, 0.31-0.76], P = 0.002). The inverse relationship between BDNF and depressive symptom risk was present in women with CVD (CES-D ≥ 16 OR, 0.63 [95% CI, 0.40-0.99], P = 0.047; CES-D ≥ 21 OR, 0.38 [95% CI, 0.21-0.70], P = 0.002) but not in men.

conclusionLower serum BDNF levels are associated with a higher risk of depressive symptoms in CVD, particularly among women. These findings implicate BDNF in the complex biological mechanisms that underlie prior associations observed between CVD and depression. To reduce the burden of depression in the large proportion of midlife and older adults with CVD, a better understanding of how BDNF may modify these pathways is merited.

Indexed as

Brain-Derived Neurotrophic FactorCardiovascular DiseasesComorbidityDepressionAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedBDNF protein, humanBrain-Derived Neurotrophic Factorbrain‐derived neurotrophic factorcardiovascular diseasescomorbiditydepressionlongitudinal studies

Identifiers

PMID38842141
PMCPMC11410362

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.